中國生物科技服務(08037.HK)2021年營收達6.24億港元,毛利率升至57.40%
格隆匯3月29日丨中國生物科技服務(08037.HK)公吿,截至2021年12月31日止12個月,公司收入達6.24億港元,毛利達3.58億港元,同比增長5.59%,年度溢利約1.33億港元。於2021年年度內,在香港提供醫學實驗室檢測服務及健康檢查服務仍然為集團營業額的主要來源,佔年度綜合營業額超過97.44%。
2021年年度的毛利率約為57.40%,較2020年年度的毛利率約51.71%上升約5.69個百分點。於2021年年度,毛利增加以及毛利率改善乃由於該期間內核酸檢測服務所使用之檢測物料整體成本下降所致。來自非核酸檢測相關的醫學實驗室檢測服務及健康檢查服務之營業額增長亦有助推高毛利及毛利率。
展望2022年,集團訂立目標,因應由COVID-19疫情轉變為疫情後時代,需求如有任何變化,會同步加強提供核酸檢測服務。集團即將推出更多新的醫學實驗室檢測服務及健康檢查服務,使精準診斷服務的範圍更加豐富,並以病人為本。根據排程表內臨牀試驗及實驗室研究完成的情況,集團預期,在免疫細胞治療的研究和發展方面會取得更加令人振奮的進展。加上海南省商業化項目啟動,引進硼中子技術作癌症治療,集團在加強旗下精準治療業務,特別是治療血及實體腫瘤方面,正向前邁出一大步。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.